Bonato Vittoria, Cataldo Dorica, Dotta Francesco, Carmellini Mario
Curr Diab Rep. 2009 Aug;9(4):317-23. doi: 10.1007/s11892-009-0049-y.
The availability of new immunosuppressive drugs has led to improvement in outcome for transplanted patients, but these drugs have also led to the increase of metabolic abnormalities, such as dyslipidemia and hyperglycemia, which can affect graft and patient outcome. Posttransplant diabetes mellitus (PTDM) or new-onset diabetes after transplantation is defined as the onset of diabetes in previously nondiabetic transplant recipients. Several clinical studies have demonstrated the involvement of PTDM in death due to infectious and cardiovascular disease. This article reviews recent concepts on pathophysiology, diagnosis, and treatment of PTDM.
新型免疫抑制药物的出现改善了移植患者的预后，但这些药物也导致了代谢异常的增加，如血脂异常和高血糖，而这些异常会影响移植物和患者的预后。移植后糖尿病（PTDM）或移植后新发糖尿病被定义为既往无糖尿病的移植受者出现糖尿病。多项临床研究表明，PTDM与感染性疾病和心血管疾病导致的死亡有关。本文综述了PTDM病理生理学、诊断和治疗方面的最新概念。
